- Home
- Industry Reports
- Healthcare
- Pharmaceuticals
- Diabetes Drug Market- Size, Outlook, Trends and Forecast (2024 – 2032)
Diabetes is often referred by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond properly to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).
Diabetes Drugs Market Share:
Oral Diabetic Medication Drugs segment is expected to hold the largest share in the Global Diabetes Drugs Market in the forecast period 2018-2014.
Diabetes Drugs Market Size:
The diabetes drugs market, valued as a USD 30.98 billion market in 2018, is expected to grow at an exponential rate and become a USD 44.55 billion market by 2024, at a CAGR of about 7.7%.
Among North America, South America, Europe, Middle East & Africa, Asia-Pacific, North American Diabetes Drugs market holds the major share in the world market scenario. The market is valued at $22 billion in 2018 and is expected to reach $36.9 billion by the end of 2024 with a CAGR of 8.7%.
Diabetes Drugs Market Growth:
Rise in the number of diabetics, Complexities in alternative diabetic therapies, Strong encouragement from the governments are the major factors that are driving the growth of the market.
Diabetes Drugs Market Industry Analysis:
The market is segmented on the basis of diabetic drugs, devices, and geography. The diabetic drugs market is again segmented into categories, which are insulin derivatives and oral diabetic medication drugs. On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the World.
Diabetes Drugs Market Outlook:
The Diabetes market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose linked transporter 2 (SGLT-2) inhibitors.
Diabetes Drugs Market Trends:
Abbott had announced that the FreeStyle Libre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome. GSK submitted a supplemental Biologics License Application (sBLA) for mepolizumab, an interleukin-5 (IL-5) antagonist.
Diabetes Drugs Market Research report includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
- Expertise investment opportunities by an analyst to the individual and organization to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Abbott Laboratories
- AstraZeneca PLC
- Bayer Healthcare AG
- Dexcom Inc.
- GlaxoSmithKline PLC
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Drugs
6.1 Insulin Derivatives
6.1.1 Long-acting insulin
6.1.2 Intermediate-acting insulin
6.1.3 Rapid-acting insulin
6.2 Oral Diabetic Medication Drugs
6.2.1 GPP4-Inhibitors
6.2.2 Meglitinides
6.2.3 Biguanide
6.2.4 Thiazolidinediones
6.2.5 Alpha-Glucosidase inhibitor
6.2.6 Metformin
6.2.7 Sulfonylurea
Chapter 7 Market Segmentation, By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Italy
7.2.5 France
7.2.6 Russia
7.2.7 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia & New Zealand
7.3.6 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.3 Argentina
7.4.4 Others
7.5 The Middle East & Africa
7.5.1 Introduction
7.5.2 South Africa
7.5.3 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Taekwang Industrial Co. Ltd.
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiative
9.2. Sinopec
9.3. Pasupati Acrylon Ltd.
9.4. Mitsubishi Rayon Group
9.5. Kaneka Corporation
9.6. Kaltex Fibers
9.7. Jilin Chemical Fiber Group Company
9.8. Indian Acrylics Limited
9.9. Formosa Plastics Corporation
9.10. Exlan Japan Co. Ltd.
9.11. Dralon
9.12. DOLAN GmbH
9.13. CNPC
9.14. Aksa Akrilik Kimya Sanayii A.Ş.
9.15. Aditya Birla Group
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and Forecast 2018-2024(USD Million)
11.1.1 Market Estimation and Forecast by Drugs 2018-2024 (USD Million)
11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
13.2 Analyst Opinion (Market Understanding)
13.3 Investment Opportunities
Chapter 14 Appendix
14.1 List of Tables
14.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Global Report
$2,700.00 – $8,100.00
- EUR: €2,520.07 - €7,560.20
- INR: ₹225,090.13 - ₹675,270.40
- AED: د.إ9,909.00 - د.إ29,727.00
- GBP: £2,158.26 - £6,474.78
Additional information
Report Type | Extensive Report, Miniature report, Snapshot Report |
---|---|
Licence | Single User License, Team License, Corporate License |
Diabetes is often referred by doctors as diabetes mellitus, describes a group of metabolic diseases in which the person has high blood glucose (blood sugar), either because insulin production is inadequate, or because the body’s cells do not respond properly to insulin or both. Patients with high blood sugar typically experience polyuria (frequent urination), and become increasingly thirsty (polydipsia) and hungry (polyphagia).
Diabetes Drugs Market Share:
Oral Diabetic Medication Drugs segment is expected to hold the largest share in the Global Diabetes Drugs Market in the forecast period 2018-2014.
Diabetes Drugs Market Size:
The diabetes drugs market, valued as a USD 30.98 billion market in 2018, is expected to grow at an exponential rate and become a USD 44.55 billion market by 2024, at a CAGR of about 7.7%.
Among North America, South America, Europe, Middle East & Africa, Asia-Pacific, North American Diabetes Drugs market holds the major share in the world market scenario. The market is valued at $22 billion in 2018 and is expected to reach $36.9 billion by the end of 2024 with a CAGR of 8.7%.
Diabetes Drugs Market Growth:
Rise in the number of diabetics, Complexities in alternative diabetic therapies, Strong encouragement from the governments are the major factors that are driving the growth of the market.
Diabetes Drugs Market Industry Analysis:
The market is segmented on the basis of diabetic drugs, devices, and geography. The diabetic drugs market is again segmented into categories, which are insulin derivatives and oral diabetic medication drugs. On the basis of geography, the market is segmented into North America, Europe, Asia-Pacific and the Rest of the World.
Diabetes Drugs Market Outlook:
The Diabetes market has undergone a dynamic shift over the past decade, primarily due to the entry of three new non-insulin drug classes for T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase 4 (DPP-4) inhibitors, and sodium-glucose linked transporter 2 (SGLT-2) inhibitors.
Diabetes Drugs Market Trends:
Abbott had announced that the FreeStyle Libre System, the company’s revolutionary new continuous glucose monitoring (CGM) system, is now available to Medicare patients, having met the codes for therapeutic CGM systems used for coverage by the U.S. Centers for Medicare & Medicaid Services (CMS). GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome. GSK submitted a supplemental Biologics License Application (sBLA) for mepolizumab, an interleukin-5 (IL-5) antagonist.
Diabetes Drugs Market Research report includes:
- An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
- To have complete market analysis through industry value chain analysis, Porter’s five, PESTLE, SWOTanalysis, and Y-o-Y analysis.
- Regional and global diversity is analyzed with the major countries and the unions. Scrutinizing the revenue generation on Year–On–Year
- Identifying DROC in the current market and their impact in altering the market dynamics.
- Competitive landscape analysis to identify the merger and acquisition which will have a comparative financial analysis with major competitors.
- Expertise investment opportunities by an analyst to the individual and organization to have a better foothold in the market.
- Identify the latest developments, market shares and strategies that are employed by the major market players, such as
- Abbott Laboratories
- AstraZeneca PLC
- Bayer Healthcare AG
- Dexcom Inc.
- GlaxoSmithKline PLC
Chapter 1 Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
Chapter 2 Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
Chapter 3 Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threat
3.5 Y-O-Y Analyses
Chapter 4 Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
Chapter 5 Market Segmentation Analysis
Chapter 6 Market Segmentation, By Drugs
6.1 Insulin Derivatives
6.1.1 Long-acting insulin
6.1.2 Intermediate-acting insulin
6.1.3 Rapid-acting insulin
6.2 Oral Diabetic Medication Drugs
6.2.1 GPP4-Inhibitors
6.2.2 Meglitinides
6.2.3 Biguanide
6.2.4 Thiazolidinediones
6.2.5 Alpha-Glucosidase inhibitor
6.2.6 Metformin
6.2.7 Sulfonylurea
Chapter 7 Market Segmentation, By Geography
7.1 North America
7.1.1 Introduction
7.1.2 United States
7.1.3 Canada
7.1.4 Mexico
7.1.5 Others
7.2 Europe
7.2.1 Introduction
7.2.2 U.K
7.2.3 Spain
7.2.4 Italy
7.2.5 France
7.2.6 Russia
7.2.7 Others
7.3 Asia-Pacific
7.3.1 Introduction
7.3.2 China
7.3.3 India
7.3.4 Japan
7.3.5 Australia & New Zealand
7.3.6 Others
7.4 South America
7.4.1 Introduction
7.4.2 Brazil
7.4.3 Argentina
7.4.4 Others
7.5 The Middle East & Africa
7.5.1 Introduction
7.5.2 South Africa
7.5.3 Others
Chapter 8 Competitive Landscape
8.1 Mergers & Acquisitions, Joint Ventures, Collaborations, and Agreements
8.2 Market Share Analysis
8.3 Strategies Adopted By Top Companies
Chapter 9 Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
9.1. Taekwang Industrial Co. Ltd.
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiative
9.2. Sinopec
9.3. Pasupati Acrylon Ltd.
9.4. Mitsubishi Rayon Group
9.5. Kaneka Corporation
9.6. Kaltex Fibers
9.7. Jilin Chemical Fiber Group Company
9.8. Indian Acrylics Limited
9.9. Formosa Plastics Corporation
9.10. Exlan Japan Co. Ltd.
9.11. Dralon
9.12. DOLAN GmbH
9.13. CNPC
9.14. Aksa Akrilik Kimya Sanayii A.Ş.
9.15. Aditya Birla Group
Chapter 11 Market Estimates and Forecast
11.1 Market Estimates and Forecast 2018-2024(USD Million)
11.1.1 Market Estimation and Forecast by Drugs 2018-2024 (USD Million)
11.1.2 Market Estimates and Forecast by Geography 2018-2024 (USD Million)
Chapter 12 Market Insights
12.1 Insights of Industry Experts
13.2 Analyst Opinion (Market Understanding)
13.3 Investment Opportunities
Chapter 14 Appendix
14.1 List of Tables
14.2 List of Figures
- Competitive Analysis in marketing and strategic management is an assessment of the strengths and weaknesses of current and potential competitors.
- Monitoring the external and internal factors which affect the market dynamics with the aid of PESTLE analysis.
- The Regional and Global Variety is taken care of in the report.
- Year on Year basis generation of revenue is studied.
- Porter's Five Forces analyze the intensity of competition in an industry and its profitability level.
- The overview and the sustainability of the market are analyzed through SWOT.
- DROC (Drivers, Restraints, Opportunities and Challenges) is recognized in the current market scenario and see how its effect on market dynamics.
- The segment-level analysis in terms of type and technology.
- The value chain analysis, value that's created and captured by a company is the profit margin.
- Value Created and Captured – Cost of Creating that Value = Margin
- An executive summary consists of the whole report and the outcome is been given in the report to have brief knowledge about the report.
- Basis on the depth of the study we approach using analytical tools
- Expertise investment opportunities are given after analyzing the market to give the organization and the individual to have perfect knowledge about the market.
Our Clientele
Exclusive Benefits
Credibility and Transparency
We actively recruit consumers, business professionals, and hard-to-reach individuals as members of our research panels, and we build trusted, ongoing relationships with them. Thus we provide the complete list of primary and secondary data sources in the report to maintain the transparency and to assure the credibility.
Exhaustive Coverage
Detailed and extensive coverage in the geography.Survey consultation for brand tracking, concept testing, consumer behaviour, and more, we have you covered with market research services that scale to meet your needs.
Competitive Edge
Our reports cover most recent updates in the market till the date of the purchase. We identify, gather and timely deliver analysis on impact of unprecedented decisions of CXOs in COVID-19 catastrophe on many businesses, their clients and their clients' clients without additional cost.
Golden Opportunities
A comprehensive strategic sieve analysis of the market by our analysts and consultants, aided by AI tools helps us find the non-obvious, golden and emerging opportunities for you to evaluate.
Top-notch Reports Guaranteed
70% of our research is exclusive; no other research firm has the depth and breadth of our research.
Post Purchase Support
Post-purchase support is provided for all our reports, for three months from the date of purchase, where related queries will be answered within 24 business hours over telephone or email.